Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study

被引:9
|
作者
Chen ZhenPing [1 ]
Li PeiJing [1 ]
Li Gang [1 ]
Tang Ling [1 ]
Zhen YingZi [1 ]
Wu XinYi [1 ]
Cheng XiaoLing [1 ]
Hung Luke Koon [2 ]
Blanchette Victor S [3 ]
Poon ManChiu [4 ]
Ding QiuLan [5 ]
Wu RunHui
机构
[1] Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, Beijing 100045, China
[2] Department of Medicine, Pediatrics and Oncology, and Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, University of Calgary, Foothills Hospital and Calgary Health Region, Calgary, Alberta, T2N2T9, Canada
[3] Department of Pediatrics and Laboratory Medicine, and Hemophilia Clinic, Children’s Hospital of Eastern Ontario and University of Ottawa, Ottawa, Ontario, K1H 8L1, Canada
[4] Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China
[5] Department of Pediatrics and Child Health Evaluative Sciences, Division of Hematology/Oncology, Research Institute, Hospital for Sick Children, University of Toronto, Toronto, Ontario, M5G 1X8, Canada
关键词
Boys; Factor VIII; Hemophilia A; Pharmacokinetics;
D O I
暂无
中图分类号
R554.1 [];
学科分类号
1002 ; 100201 ;
摘要
Background: Although much attention has been paid to the pharmacokinetics (PKs) of different factor VIII (FVIII) concentrates in persons with hemophilia A (HA), limited information is available in young boys with severe HA. In this study, we aimed to assess the PK parameters of FVIII products in boys with severe HA in China.Methods: A total of 36 boys (plasma-derived [pd]-FVIII,n = 15; recombinant [r] FVIII,n = 21) were enrolled between January 2015 and May 2016 in Beijing Children’s Hospital. PK characteristics of FVIII products were studied according to a reduced 4-sampling time point design (1 h, 9 h, 24 h, and 48 h postinfusion).Results: The mean FVIII half-life (t1/2) was 10.99 ± 3 .45 h (range 5.52- 20.02 h), the meanin vivo recovery (IVR) was 2.01 ± 0.42 IU/dl per IU/kg (range 1.24–3.02 IU/dl per IU/kg) and mean clearance (CL) of FVIII is 4.34 ± 1.58 ml·kg?1·h?1 (range 2.29–7.90 ml·kg?1·h?1). We also analyzed the influence of several parameters that potentially modulate FVIII PK. The age was closely associated with FVIII half-life (R2 = 0.32,P< 0.01). The t1/2 of FVIII increased by 0.59 h per year. Besides age, von Willebrand factor antigen (VWF:Ag) also was associated with FVIII half-life (R2 = 0.52,P< 0.01). Patients with blood Group O had a shorter FVIII half-life than patients with non-O blood group (9.40 ± 0.68 h vs. 12.3 ± 0.79 h,t = 2.70,P= 0.01). The FVIII IVR correlated with age (R2 = 0.21,P< 0.01) and VWF:Ag level (R2 = 0.28,P< 0.01). CL rates were faster in young patients and in those with low-VWF:Ag levels. CL rates of FVIII are higher in blood Group O versus non-blood Group O persons (5.02 ± 0.38 vs. 4.00 ± 0.32 ml·kg?1·h?1,t= 2.53,P= 0.02).Conclusions: Chinese boys with severe HA have similar PK values to other ethnic groups and large differences in FVIII PK between individual patients. Age, blood group, and VWF:Ag levels are important determining factors for FVIII CL.
引用
收藏
页码:1780 / 1785
页数:6
相关论文
共 50 条
  • [1] Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study
    Chen, Zhen-Ping
    Li, Pei-Jing
    Li, Gang
    Tang, Ling
    Zhen, Ying-Zi
    Wu, Xin-Yi
    Cheng, Xiao-Ling
    Luke, Koon Hung
    Blanchette, Victor S.
    Poon, Man-Chiu
    Ding, Qiu-Lan
    Wu, Run-Hui
    CHINESE MEDICAL JOURNAL, 2018, 131 (15) : 1781 - U28
  • [2] Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A
    Chen, Zhenping
    Huang, Kun
    Li, Gang
    Zhen, Yingzi
    Wu, Xinyi
    Ai, Di
    Liu, Guoqing
    Li, Zekun
    Alfonso, Iorio
    Wu, Runhui
    PEDIATRIC INVESTIGATION, 2021, 5 (01) : 38 - 45
  • [3] Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A
    Chen Zhenping
    Huang Kun
    Li Gang
    Zhen Yingzi
    Wu Xinyi
    Ai Di
    Liu Guoqing
    Li Zekun
    Alfonso Iorio
    Wu Runhui
    儿科学研究(英文), 2021, 05 (01) : 38 - 45
  • [4] A 5-Year Single-center Experience on the Use of Emicizumab Prophylaxis in Children With Severe Hemophilia A With and Without Factor VIII Inhibitors
    Hasan, Esraa Mohamed Ahmed
    Motwani, Jayashree
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2025, 47 (02) : e83 - e89
  • [5] Factor VIII/factor IX prophylaxis for severe hemophilia
    Carcao, Manuel
    Srivastava, Alok
    SEMINARS IN HEMATOLOGY, 2016, 53 (01) : 3 - 9
  • [6] Relationship between mutations in severe hemophilia A and risk of inhibitor development: A large single-center study
    Moghadam, Arash Ahmadfard
    Manafzadeh, Amir Reza
    Nikoonia, Mr
    Moazezi, Seyedeh Somayeh
    Nekoei, Khadijeh Dajliry
    Ramezan, Farahnaz
    Bashash, Davood
    Hamidpour, Mohsen
    Tabibian, Shadi
    TRANSFUSION AND APHERESIS SCIENCE, 2024, 63 (06)
  • [7] Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A
    Castaman, Giancarlo
    Linari, Silvia
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (02) : 143 - 151
  • [8] Pharmacokinetic evaluation of efanesoctocog alfa: breakthrough factor VIII therapy for hemophilia A
    Yada, Koji
    Nogami, Keiji
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2024, : 5 - 14
  • [9] Iliopsoas hematoma in patients with hemophilia:: A single-center study
    Dauty, Marc
    Sigaud, Marianne
    Trossaert, Marc
    Fressinaud, Edith
    Letenneur, Joseph
    Dubois, Charles
    JOINT BONE SPINE, 2007, 74 (02) : 179 - 183
  • [10] The factor VIII treatment history of non-severe hemophilia A
    Abdi, Amal
    Kloosterman, Fabienne R.
    Eckhardt, Corien L.
    Male, Christoph
    Castaman, Giancarlo
    Fischer, Kathelijn
    Beckers, Erik A. M.
    Kruip, Marieke J. H. A.
    Peerlinck, Kathelijne
    Mancuso, Maria Elisa
    Santoro, Cristina
    Hay, Charles R.
    Platokouki, Helen
    van Der Bom, Johanna G.
    Gouw, Samantha C.
    Fijnvandraat, Karin
    Hart, Dan P.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (12) : 3203 - 3210